Atossa Therapeutics, Inc.
ATOSNASDAQHealthcare● Active
$4.55
+$0.08(+1.79%)
Market Cap$39181997
P/E Ratio—
52W High$19.35
52W Low$3.76
Atossa Therapeutics, Inc. (ATOS) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ATOS · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 8, 2026EPS Actual
-$1.11
Est. -$1.22 · +9.0%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 8, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
ATOS reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.02
Rev. $0.33B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.02
Rev. Est.$0.33B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$1.08 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 8, 2026 | -$1.22 | -$1.11 | +9.0% | — | — | — |
| ▼ Q1 FY2026 | Mar 25, 2026 | -$1.14 | -$1.19 | -4.6% | — | — | — |
| — Q4 FY2025 | Nov 12, 2025 | -$1.05 | -$1.05 | +0.0% | — | — | — |
| ▼ Q3 FY2025 | Aug 12, 2025 | -$0.06 | -$0.07 | -16.7% | — | — | — |
| ▲ Q2 FY2025 | May 13, 2025 | -$0.06 | -$0.05 | +16.7% | — | — | — |
| ▲ Q1 FY2025 | Mar 25, 2025 | -$0.06 | -$0.05 | +16.7% | — | — | — |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$0.06 | -$0.05 | +16.7% | — | — | — |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$1.08
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 8, 2026Beat
EPS Actual
-$1.11
EPS Est.
-$1.22
EPS Surpr.
+9.0%
Revenue
—
Q1 FY2026
Mar 25, 2026Miss
EPS Actual
-$1.19
EPS Est.
-$1.14
EPS Surpr.
-4.6%
Revenue
—
Q4 FY2025
Nov 12, 2025
EPS Actual
-$1.05
EPS Est.
-$1.05
EPS Surpr.
+0.0%
Revenue
—
Q3 FY2025
Aug 12, 2025Miss
EPS Actual
-$0.07
EPS Est.
-$0.06
EPS Surpr.
-16.7%
Revenue
—
Q2 FY2025
May 13, 2025Beat
EPS Actual
-$0.05
EPS Est.
-$0.06
EPS Surpr.
+16.7%
Revenue
—
Q1 FY2025
Mar 25, 2025Beat
EPS Actual
-$0.05
EPS Est.
-$0.06
EPS Surpr.
+16.7%
Revenue
—
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$0.05
EPS Est.
-$0.06
EPS Surpr.
+16.7%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.87 | $-0.87 | $-0.87 | 1 |
| Q3 FY2027 | $-0.86 | $-0.86 | $-0.86 | 1 |
| Q2 FY2027 | $-0.84 | $-0.84 | $-0.84 | 1 |
| Q1 FY2027 | $-0.83 | $-0.83 | $-0.83 | 1 |
| Q4 FY2026 | $-1.10 | $-1.10 | $-1.10 | 1 |
| Q3 FY2026 | $-1.23 | $-1.12 | $-1.03 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 8, 2026 | +9.0% | $5.67 | $5.60 | -1.23% |
| ▼ Q1 FY2026 | Mar 25, 2026 | -4.6% | $5.51 | $5.42 | -1.63% |
| ▲ Q4 FY2025 | Nov 12, 2025 | +0.0% | $12.42 | $12.20 | -1.77% |
| ▼ Q3 FY2025 | Aug 12, 2025 | -16.7% | $11.45 | $11.59 | +1.22% |
| ▲ Q2 FY2025 | May 13, 2025 | +16.7% | $12.55 | $13.35 | +6.37% |
| ▲ Q1 FY2025 | Mar 25, 2025 | +16.7% | $11.23 | $10.86 | -3.29% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +16.7% | $24.30 | $22.50 | -7.41% |
| ▲ Q3 FY2024 | Aug 12, 2024 | +0.0% | $17.55 | $18.60 | +5.98% |
Q2 FY2026-1.23%
Report Date
May 8, 2026
EPS Beat/Miss
+9.0%
Price Before
$5.67
Price After
$5.60
Q1 FY2026-1.63%
Report Date
Mar 25, 2026
EPS Beat/Miss
-4.6%
Price Before
$5.51
Price After
$5.42
Q4 FY2025-1.77%
Report Date
Nov 12, 2025
EPS Beat/Miss
+0.0%
Price Before
$12.42
Price After
$12.20
Q3 FY2025+1.22%
Report Date
Aug 12, 2025
EPS Beat/Miss
-16.7%
Price Before
$11.45
Price After
$11.59
Q2 FY2025+6.37%
Report Date
May 13, 2025
EPS Beat/Miss
+16.7%
Price Before
$12.55
Price After
$13.35
Q1 FY2025-3.29%
Report Date
Mar 25, 2025
EPS Beat/Miss
+16.7%
Price Before
$11.23
Price After
$10.86
Q4 FY2024-7.41%
Report Date
Nov 12, 2024
EPS Beat/Miss
+16.7%
Price Before
$24.30
Price After
$22.50
Q3 FY2024+5.98%
Report Date
Aug 12, 2024
EPS Beat/Miss
+0.0%
Price Before
$17.55
Price After
$18.60
Avg Beat Reaction-0.22%
Avg Miss Reaction-0.20%
Beat Rate6 / 8 quarters
Largest Move-7.41% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ATOS ends December
Atossa Therapeutics, Inc. (ATOS) most recently reported earnings on May 8, 2026 for Q2 FY2026, posting EPS of $-1.11 — beating the analyst consensus of $-1.22 by +9.0%. The next ATOS earnings date is expected around September 1, 2026.
Each quarter, investors track ATOS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ATOS revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ATOS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ATOS earnings · 5 questionsAtossa Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. ATOS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ATOS historically reports after market close (AMC).
ATOS earnings datewhen is ATOS earningsATOS next earnings datewhen does ATOS report earningsATOS earnings calendar
▸ Source: FMP · Atossa Therapeutics, Inc. SEC filings · US GAAP · Atossa Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026